The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: A time-trend study

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 6, 2014, Pages 629-638

  Reich, K M ^a   Chang, H J ^a   Rezaie, A ^b   Wang, H ^a   Goodman, K J ^a   Kaplan, G G ^b   Svenson, L W ^c   Lees, G ^a   Fedorak, R N ^a   Kroeker, K I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Surveillance and Assessment   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COLON RESECTION; DRUG USE; DRUG UTILIZATION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREND STUDY; ULCERATIVE COLITIS;

ADULT; ALBERTA; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906271087     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12873     Document Type: Article

References (32)

1. Molodecky NA, Soon IS, Rabi DM, et al,. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54 e42.
2. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ,. Ulcerative colitis. Lancet 2012; 380: 1606-19.
3. Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A,. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol 2012; 18: 1861-70.
4. Cima RR,. Timing and indications for colectomy in chronic ulcerative colitis: surgical consideration. Dig Dis 2010; 28: 501-7.
5. de Silva S, Ma C, Proulx MC, et al,. Postoperative complications and mortality following a colectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 972-80.
6. Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE,. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008; 134: 680-7.
7. Frolkis AD, Dykeman J, Negrõn ME, et al,. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013; 145: 996-1006.
8. Leijonmarck CE, Persson PG, Hellers G,. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990; 31: 329-33.
9. Hoie O, Wolters FL, Riis L, et al,. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132: 507-15.
10. Solberg IC, Lygren I, Jahnsen J, et al,. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-40.
11. Targownik LE, Singh H, Nugent Z, Bernstein CN,. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012; 107: 1228-35.
12. Kaplan GG, Seow CH, Ghosh S, et al,. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012; 107: 1879-87.
13. Moore SE, McGrail KM, Peterson S, et al,. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum 2014; 57: 83-90.
14. Gisbert JP, Linares PM, McNicholl AG, Mate K, Gomollon F,. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009; 30: 126-37.
15. Nugent Z, Targownik LE, Bernstein CN,. Prescription drug use in IBD: a population based study. Gastroenterology 2011; 140 (Suppl. 1): S778-9.
16. Moskovitz DN, Van Assche G, Maenhout B, et al,. Incidence of colectomy during long-term follow up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-5.
17. Campbell S, Travis SPL, Jewell DP,. Ciclosporin use in acute severe ulcerative colitis: a long term experience. EurJ Gastroenterol Hepatol 2005; 17: 79-84.
18. Järnerot G, Hertervig E, Friis-Liby I, et al,. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
19. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
20. Sandborn WJ, van Assche G, Reinisch W, et al,. Adalimumab induces and maintains clinical remission in patients with moderate-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
21. Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott DR,. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther 2013; 38: 925-45.
22. Croft A, Walsh A, Doecke K, Cooley R, Howlett M, Radford-Smith G,. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013; 38: 294-302.
23. Sandborn WJ, Rutgeerts P, Feagan BG, et al,. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60.
24. Ma C, Crespin M, Proulx M-C, et al,. Postoperative complications following colectomy for ulcerative colitis: a validation study. BMC Gastroenterol 2012; 12: 39.
25. Rezaie A, Quan H, Fedorak RN, Panaccione R, Hilsden RJ,. Development and validation of an administrative case definition for inflammatory bowel diseases. Can J Gastroenterol 2012; 26: 711-7.
26. Statistics Canada. Table 051-0046-Estimates of population by census metropolitan area, sex and age group for July 1, based on the Standard Geographical Classification (SGC) 2006, annual (persons), CANSIM (database). Accessed 14 August 2012.
27. Wold S,. Spline functions in data analysis. Technometrics 1974; 16: 1-11.
28. Joinpoint Regression Program [Internet]. Bethesda: Surveillance Research Program, National Cancer Institute; [date unknown]. Available from: http://surveillance.cancer.gov/joinpoint/. [updated 2013 May 6; cited 2014 January 7]
29. Sjoberg M, Magnuson A, Bjork J, et al,. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013; 38: 377-87.
30. Gustavsson A, Jarnerot G, Hertervig E, et al,. Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32: 984-9.
31. Soon IS, Wrobel I, deBruyn JCC, et al,. Postoperative complications following colectomy for ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2012; 54: 763-8.
32. Danese S, Colombel J-F, Peyrin-Biroulet L, Rutgeerts P, Reinisch W,. Review article: the role of anti-TNF in the management of ulcerative colitis-past, present and future. Aliment Pharmacol Ther 2013; 37: 855-66.